Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Insulin Icodec (Insulin 287) in Japanese T1D
NCT03766854Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin icodec in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the serum insulin 287 concentration-time curve during one dosing interval at steady state. Started Dec 2018; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03766854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766854.